文献速递中医内科中药与中成药合理使用

动物双歧杆菌乳亚种BAMA-B06/BAu-B0111辅助六味安消胶囊改善帕金森病便秘的随机对照研究

The adjunct use of Bifidobacterium animalis subsp. lactis BAMA-B06/BAu-B0111 improves the therapeutic efficacy of Liuwei'anxiao Capsule in alleviating constipation in Parkinson's Disease: A randomized controlled study.
PubMed 文献 · J Ethnopharmacol · 2026-04-15

该随机对照研究纳入105例帕金森病便秘患者,分为六味安消胶囊组、益生菌组和联合组。结果显示联合组便秘改善总有效率最高,且能恢复与临床结局相关的双歧杆菌等菌群丰度,提示益生菌辅助可增强六味安消胶囊疗效。

要点

  • 益生菌辅助六味安消胶囊可提高帕金森病便秘的改善总有效率。
  • 联合治疗可能通过调节肠道菌群(双歧杆菌、巨单胞菌、罗斯氏菌)发挥作用。
  • 各治疗组Wexner评分、PAC-QOL评分及每周SBM频率均显著改善。

核心结论

  • 益生菌辅助六味安消胶囊可通过调节肠道菌群提高帕金森病便秘患者的疗效。

研究设计与样本

  • 随机对照研究,最终纳入105例帕金森病便秘患者,分为六味安消胶囊组、益生菌组和联合组。

主要发现

  • 所有组Wexner和PAC-QOL评分及每周SBM频率均显著改善(P < 0.001)。
  • 六味安消胶囊组和联合组BSS评分显著改善。
  • 便秘改善总有效率:六味安消胶囊组60.00%,益生菌组56.67%,联合组72.41%。
  • 联合组显著恢复与临床结局改善密切相关的双歧杆菌、巨单胞菌和罗斯氏菌相对丰度。

关键数值与推荐

  • 便秘改善总有效率:六味安消胶囊组60.00%,益生菌组56.67%,联合组72.41%。
  • 所有组Wexner和PAC-QOL评分及每周SBM频率改善的P值均小于0.001。

临床怎么用

  • 对帕金森病便秘患者,可考虑在六味安消胶囊基础上联合动物双歧杆菌乳亚种BAMA-B06/BAu-B0111以增强疗效。
  • 联合治疗可能通过调节肠道菌群(增加双歧杆菌、巨单胞菌、罗斯氏菌)改善便秘症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Liuwei'anxiao Capsule (LAC), a well-established Chinese patent medicine (CPM) that derived from the Mongolian and Tibetan folk prescription "Liuwei Anxiao San", has demonstrated efficacy in treating constipation but can cause side effects when used improperly. Probiotics offer a promising adjunct to enhance CPM efficacy and safety while minimizing their side effects. AIM OF THE STUDY: In this clinical trial, a probiotic strain Bifidobacterium animalis subsp. lactis BAMA-B06/BAu-B0111 was employed to potentiate the efficacy of LAC in relieving Parkinson's disease (PD) constipation, a common non-motor symptom significantly reducing quality of life and potentially exacerbating disease progression in PD patients. MATERIALS AND METHODS: A total of 105 PD patients with constipation were ultimately randomized into three groups: LAC alone (L group), probiotic of B. animalis subsp. lactis alone (P group), and the combination (LP group). Motor symptoms were assessed using the Hoehn and Yahr scale and the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III at baseline and post-treatment. Constipation severity was evaluated using weekly spontaneous bowel movement (SBM) frequency, Bristol Stool Scale (BSS) scores, Wexner Constipation Score, Patient Assessment of Constipation Quality of Life (PAC-QOL) questionnaire, and the total effective rate of symptom improvement. Additionally, gut microbiota composition was analyzed by 16S rRNA high-throughput sequencing. RESULTS: All groups showed significant improvements in Wexner and PAC-QOL scores and increased weekly SBM frequency (P < 0.001). In addition, LAC and combination therapy notably improved stool morphology, as indicated by the BSS scores. And the overall effective rates of constipation improvement were 60.00%, 56.67%, and 72.41% for the L, P, and LP groups, respectively. The LP group significantly restored the relative abundance of Bifidobacterium, Megamonas, and Roseburia that were closely associated with the improved clinical outcomes, indicating a potential gut microbiota-mediated mechanism underlying the improved efficacy of combining therapy. CONCLUSION: The adjunct use of probiotics contributed to the better therapeutic efficacy of LAC in alleviating constipation symptoms via modulating the gut microbiota in PD patients, suggesting a beneficial combined application of LAC and probiotic in managing PD-related constipation.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Lin M, Li S, Lin J, et al. The adjunct use of Bifidobacterium animalis subsp. lactis BAMA-B06/BAu-B0111 improves the therapeutic efficacy of Liuwei'anxiao Capsule in alleviating constipation in Parkinson's Disease: A randomized controlled study. J Ethnopharmacol. 2026. PMID: 41990927. doi:10.1016/j.jep.2026.121694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。